The Mind Medicine Australia Podcast aims to facilitate engagement between clinicians, researchers, mental health practitioners, and leaders in psychedelic-assisted therapies to provide expert opinion, share research results, and ultimately help to educate the public about potential new opportunities for patient treatment.
#16 - Prof David Nutt: The Neuroscience Of Psychedelics, Addiction, And How Drugs Help Us Understand The Brain
Prof David Nutt is Neuropsychopharmacologist specialising in the research of drugs that affect the brain and conditions such as addiction, anxiety, and sleep. He is the chairman of Drug Science, a non-profit which he founded in 2010 to provide independent, evidence-based information on drugs.
#15 - Dennis McKenna: Catalysing A Global Transformation Of Human Consciousness
Dennis McKenna is an Ethnopharmacolgist, research pharmacist, lecturer, and author. He is the brother of the famous psychedelic advocate Terence McKenna and is a founding member and director of ethnographic research at the Heffter Research Institute, a non-profit organization involved in investigating the potential of therapeutic uses of drugs.
#14 - Andrew Robb AO, MP: Psychedelic Medicine Is The Future Of Mental Health Care
Andrew Robb was Australia’s Minister for Trade, Investment, and Tourism. Currently, he is the chairman of The Robb Group (corporate and investment advisory company), and is a board member for multiple organizations, including Mind Medicine Australia. He is the author of Black Dog Daze: Public Life, Private Demons, his memoir that explores the challenges of managing depression, political ambition, and the life of the liberal party.
#13 - Nigel Denning: Opening Up To A New Possibility Of Mind
Nigel is the Director and Counselling Psychologist at Integrative Psychology He is a former Family Violence Co-ordinator for Relationships Australia and is the Deputy President of the In Good Faith Foundation.
#12 - Lars Wilde: Scaling The Model For Psilocybin-Assisted Psychotherapy
Lars Wilde is the President, Chief Business Officer, and Co-founder of COMPASS Pathways. COMPASS is a UK life sciences company that works to expedite the approval and delivery of mental health therapies to patients and focuses primarily on testing psilocybin for use in patients with treatment-resistant depression (TRD).
#11 - David. B. Yaden, Ph.D.: Transcending Time, Space, and Self
David Bryce Yaden, Ph.D. is a Postdoctoral Research Fellow at Johns Hopkins Medicine in The Center for Psychedelic and Consciousness Research. His research focus is on the psychology, cognitive neuroscience, and psychopharmacology of spiritual, self-transcendent, and positively transformative experiences triggered with psychedelic substances and other means. Specifically, he is interested in understanding how these experiences can result in long-term changes to well-being and how they temporarily alter fundamental faculties of consciousness such as the sense of time, space, and self.